CSNK2A1 and prostate carcinoma: An excellent example of this was shown in a prostate cancer mouse xenograft model, where CSNK2A1 siRNA was delivered via a nanoparticle delivery system in PC3-LN4 engrafted mice, leading to a >50% reduction in tumour volume at 10 days after the start of treatment (p = 0.005) [67].